With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.5464-12-0,1-(2-Hydroxyethyl)-4-methylpiperazine,as a common compound, the synthetic route is as follows.
To a solution of Intermediate 13b (1.15 g, 5.0 mmol), 2-(4-methyl- piperazin-l -yl)-ethanol (864 mg, 6.0 mmol) and triphenylphosphine (2.62 g, 10.0 mmol) in THF (10 mL) was added diisopropyl azodicarboxylate (2.0 g, 10.0 mmol) dropwise and stirred for 75 min. The mixture was diluted with diethyl ether (50 mL) and extracted with 10percent aqueous citric acid soln (2 x). The combined aqueous layers were basified with solid potassium carbonate until pH = 9. The aqueous layer was then extracted with ethyl acetate (3 x). The combined ethyl acetate layers were washed with brine, dried (NaSO4) and evaporated in vacuo. Purification by FCC using 0- 12percent [9: 1 MeOH/880 ammonia] in DCM. The resulting product was crystallised (diethyl ether) to give the title compound (270 mg, 0.756 mmol, 15percent). LCMS (Method 1): Rt 2.31 , 1.72 min, m/z 358/359 [MH+].
5464-12-0, The synthetic route of 5464-12-0 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; CHIESI FARMACEUTICI S.P.A.; VAN NIEL, Monique Bodil; RAY, Nicholas Charles; ALCARAZ, Lilian; PANCHAL, Terry Aaron; JENNINGS, Andrew Stephen Robert; ARMANI, Elisabetta; CRIDLAND, Andrew Peter; HURLEY, Cristopher; WO2013/83606; (2013); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics